Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.73

€3.73

11.680%
0.41
11.680%
-

-

 
22:26 / Tradegate WKN: A2PF3F / Name: PDS Biotech / Stock / Biotechnology & Medical Research / Micro Cap /
Latest predictions
16.03.24
-19.31%
buy
Your prediction

PDS Biotechnology Corp. Stock

A very strong showing by PDS Biotechnology Corp. today, with an increase of €0.41 (11.680%) compared to yesterday's price.
For the coming years our community has positive and negative things to say abot the PDS Biotechnology Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.

Pros and Cons of PDS Biotechnology Corp. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of PDS Biotechnology Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
PDS Biotechnology Corp. 11.680% 10.369% 16.599% -37.251% -24.647% - -
Larimar Therapeutics Inc. 2.720% 15.748% 11.364% 73.349% 80.147% -33.784% -73.177%
Vaxart Inc. -3.690% 2.673% -30.292% -11.956% 34.116% -88.307% -
Jaguar Health Inc. -7.240% 37.512% 256.645% 253.453% 83.046% -99.885% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-27

PDS Biotech, a prominent player in the biotechnology and medical research industry, appears to be in a somewhat strong financial position based on the data provided. The company has a sizable amount of cash on hand and has been consistently increasing its total assets over the years. However, the data also reveals certain areas of concern, such as growing net losses and a lack of revenue generation. In this article, we will delve deep into the financials of the company and discuss both the positives and negatives.

Growing Total Assets: PDS Biotech has displayed a consistent growth in its total assets over the years, increasing from $30,890,379 in 2020 to $77,007,923 in 2022. This trend signifies the company's ability to accumulate assets, which can potentially be used to finance future growth.

Solid Cash Position: The company has maintained a strong cash position throughout the years. Cash reserves increased from $28,839,565 in 2020 to $73,820,160 in 2022. This large cash balance provides the company with financial flexibility and can be used to support ongoing research and development efforts as well as fuel potential acquisitions and partnerships.